Dublin, Dec. 30, 2022 (GLOBE NEWSWIRE) -- The "North America Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class, Structures, Indications, Mode of Action" report has been added to ResearchAndMarkets.com's offering.
The glycomic therapeutics market in North America is expected to grow from US$ 42,552.69 million in 2022 to US$ 1,00,790.58 million by 2028; it is estimated to grow at a CAGR of 15.5% from 2022 to 2028.
Glycan-based products have wide applications in the therapeutic industry; the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anaemia, cancer, influenza, cataract, and anti-inflammation. The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are a part of several research projects.
These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions.
For instance, in April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule, only found in cancer cells. The researchers have claimed that the protein might revolutionize cancer detection.
Market Dynamics
Market Drivers
- Wide Application in Various Disorders Followed by the Development of New Treatment Processes
- Increasing Research and Development In the Field of Glycomic Therapeutics
Market Restraints
- Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
Market Opportunities
- Wide Applications of Glycomics in Therapeutics
Future Trends
- New Tools in Glycomics Research
North America Glycomic Therapeutics Market Segmentation
The North America glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
- Based on class, the North America glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022.
- Based on structure, the North America glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022.
- Based on indications, the North America glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher's disease, MPS-1 & IV, cancer, Alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022.
- Based on mode of action, the North America glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022.
- Based on country, the North America glycomic therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); HalozymeTherapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Lt. are the leading companies operating in the glycomic therapeutics in North America.
| Report Attribute | Details |
| No. of Pages | 193 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ($) in 2022 | $42.55 Million |
| Forecasted Market Value ($) by 2028 | $100.79 Million |
| Compound Annual Growth Rate | 15.5% |
| Regions Covered | North America |
Key Topics Covered:
1. Introduction
2. North America Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
4. North America Glycomic Therapeutics Market Landscape
5. North America Glycomic Therapeutics Market - Key Market Dynamics
6. Glycomic Therapeutics Market- North America Analysis
7. North America Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
8. North America Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication
9. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
10. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action
11. North America Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Country Analysis
12. Glycomic Therapeutics Market -Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- Biomarin Pharmaceutical Inc.
- Genzyme Corporation (Sanofi)
- Halozyme Therapeutics, Inc.
- Bayer Ag
- Alzheon, Inc.
- Glycomar
- Glaxosmithkline Plc.
- F. Hoffmann-La Roche Ltd
For more information about this report visit https://www.researchandmarkets.com/r/3gk3oe
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
